Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Brian Moore who wrote (17753)	3/20/1998 3:43:00 AM
From: SnowShredder	Read Replies (1) \| Respond to of 32384

(Off topic) Brian, I've only managed my own portfolio for about 3 months now (I've learned a lot). One biotech that has gone up over 33%...is GZTC. I believe that they have excellent technology and potential. Take everything you read with a grain of salt. If an analyst says that a biotech company is a buy in the short term or long...do your own research and come to your own conclusion. Some analysts just look @ a product nearing the end of trials...but do not analyze the science behind the drug...thus when the product does not get approved they are shocked and lose $$$. Also look @ the companies management and there actions. Are they stock holder friendly? What is there strategy for getting $$$? Are they experienced? Some of the biotech companies have poor management(in my opinion), and will waste $ pursuing approval of drugs that are doing lousy in trials...thus get rejected by the FDA. Try to imagine the impact that the drugs in development will have on the market...will people use the drug? Why would people use it over its competition? What is the potential market cap? To me, great science + great management = great potential ...but it is still a risk because I'm sure that we all know people that do not live up to their potential. I hope this helps. Best of Luck Where'd He Go?

To: Brian Moore who wrote (17753)	3/20/1998 9:38:00 AM
From: tuck	Respond to of 32384

Brian, One biotech with earnings is Biotechnology General (BTGC). It has had a couple of stumbles in its pipeline lately, and the stock is thus cheap for a biotech with sales, but sales of products currently on the market are ramping nicely. Be sure to do your due diligence. Tuck

To: Brian Moore who wrote (17753)	3/20/1998 12:16:00 PM
From: Pseudo Biologist	Read Replies (2) \| Respond to of 32384

Brian, first thanks for bringing a fresh perspective to "Lake Ligand." Second, regarding your query <<This is why I was asking people who they think are the one or two most respected commentators in the field of biotech investing. I'd really like to find the names of these people and see what they have to say about the field as a whole.>> I can try to give you a short list. Here in SI I've found the insights of Richard Harmon, PeterSuzman, and Vector1 particularly useful (Henry's, of course, are great, but they tend to be, may I say, focused to Ligand). Harmon is a scientist-investor, while the other two I believe have financial backgrounds. In the world "at large" I've heard good things of a man named Sturza who pens a newsletter (fellow "pensters" Michael Murphy and Jim McCamant do not receive the same degree of respect). There is Mark Lambert who runs the Biotech Value Fund (a hedge fund?), and who has been called the "Michael Price of biotechnology." Harmon started a thread on Lampert in the Coffee Shop section of SI. Vector1 and others "run" the virtual "VD portfolio" -- check the thread here in the Biotech section of SI. Link to VD portfolio thread: Subject 14492 Link to Value Fund thread: Subject 19115 PB